CAS 1051375-16-6
:Dolutegravir
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benylamide
- 2H-Pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
- Dolutegravir free acid
- Gsk 1349572
- Gsk1349572
- S/Gsk1349572
- Soltegravir
- Tivicay
- Dolutegravir
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide
CAS:(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-CarboxamideFormula:C20H19F2N3O5Purity:98%Molecular weight:419.38Dolutegravir
CAS:DolutegravirFormula:C20H19F2N3O5Purity:98.5%Color and Shape:SolidMolecular weight:419.38Dolutegravir (Standard)
CAS:Dolutegravir (Standard) is a reference standard for research and analysis in studies involving Dolutegravir. Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.Formula:C20H19F2N3O5Molecular weight:419.38Dolutegravir-d4
CAS:Controlled ProductApplications Isotope labelled Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);Formula:C20H15D4F2N3O5Purity:>80%Color and Shape:NeatMolecular weight:423.4Dolutegravir
CAS:Applications Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);Formula:C20H19F2N3O5Color and Shape:NeatMolecular weight:419.38Dolutegravir (0.1 mg/mL in Methanol)
CAS:Formula:C20H19F2N3O5Color and Shape:Single SolutionMolecular weight:419.38Dolutegravir
CAS:Dolutegravir (GSK1349572), HIV integrase inhibitor with IC50 of 2.7 nM, partly effective against some raltegravir-resistant HIV strains.Formula:C20H19F2N3O5Purity:98.97% - 99.75%Color and Shape:SolidMolecular weight:419.38Ref: TM-T6198
1mg34.00€1mL*10mM (DMSO)64.00€5mg70.00€10mg105.00€25mg168.00€50mg222.00€100mg295.00€200mg431.00€(4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
CAS:(4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamideFormula:C20H19F2N3O5Purity:98%Molecular weight:419.38Dolutegravir
CAS:Dolutegravir is an HIV-1 integrase inhibitor. Dolutegravir is used in the treatment of HIV-1 infections as it hampers the integration of the viral genome into the host DNA (Katlama, 2012). Active on a wide number of HIV-1 phenotypes, dolutegravir is highly bioavailable with an IC90 of more than 30 hours (Cottrell, 2013).Formula:C20H19F2N3O5Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:419.40 g/mol









